Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07252232 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study acronym: RASolute 304
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 74 → 78 locations
  2. Trial sites expanded: 66 → 74 locations Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 1 of 6 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 6 entries
  3. Trial sites expanded: 60 → 66 locationsv11
  4. Trial sites expanded: 43 → 60 locationsv10
  5. Trial sites expanded: 34 → 43 locationsv9
  6. Trial sites expanded: 17 → 34 locationsv8
  7. Re-verified, no change to tracked fieldsv7
  8. Study sites: 15 to 17v6
  9. Trial sites expanded: 7 → 15 locationsv5
  10. Study sites: 5 to 7v4
  11. Start date changed from estimate of Dec 10, 2025 to Dec 15, 2025v3
  12. Study sites: 3 to 5v2
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Trial Details
NCT Number NCT07252232
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov